Key statistics
As of last trade Alvotech SA (ALVO:NMQ) traded at 4.44, 2.78% above its 52-week low of 4.32, set on Dec 03, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.68 |
|---|---|
| High | 4.69 |
| Low | 4.43 |
| Bid | 4.43 |
| Offer | 4.46 |
| Previous close | 4.64 |
| Average volume | 399.87k |
|---|---|
| Shares outstanding | 311.72m |
| Free float | 117.87m |
| P/E (TTM) | 22.17 |
| Market cap | 1.45bn USD |
| EPS (TTM) | 0.2093 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 15:06 GMT.
More ▼
Announcements
- Alvotech Announces Increase in Number of Own Shares
- Alvotech tilkynnir um aukningu í fjölda eigin bréfa
- Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
- Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio
- Alvotech gerir samninga um markaðssetningu á fyrirhuguðum hliðstæðum í Kanada, Ástralíu og Nýja-Sjálandi
- Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
- Alvotech nær samningum um alþjóðlega markaðssetningu hliðstæðu við augnlyfið Eylea
- Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
- Correction: Transactions of Managers and Closely Associated Persons
- Leiðrétting: Viðskipti stjórnenda og tengdra aðila
More ▼
